A mitochondria-targeting self-assembled carrier-free lonidamine nanodrug for redox-activated drug release to enhance cancer chemotherapy

Author:

Yang Ting12,Zhang Xianfen13,Yang Xing1,Li Ying1,Xiang Jingjing1,Xiang Chunbai1,Liu Zhongke14,Hai Luo5,Huang Saipeng3ORCID,Zhou Lihua6ORCID,Liang Ruijing1ORCID,Gong Ping1

Affiliation:

1. Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab for Biomaterials, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China

2. University of Chinese Academy of Sciences, Beijing, 100049, P. R. China

3. School of Chemical Engineering, Northwest University, Xi’an, 710069, P. R. China

4. Nano Science and Technology Institute, University of Science & Technology of China, Suzhou, 215123, P. R. China

5. Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, P. R. China

6. School of Applied Biology, Shenzhen Institute of Technology, No. 1 Jiangjunmao, Shenzhen, 518116, P. R. China

Abstract

Self-assembled carrier-free nanoparticles based on a prodrug enhance tumor chemotherapy through mitochondrial targeting, redox-activated drug release, and apoptotic pathway activation.

Funder

National Natural Science Foundation of China

National Key Research and Development Program of China

Shenzhen Science and Technology Innovation Program

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering,General Chemistry,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3